ClinicalTrials.gg
Not yet recruitingNCT07812597Updated Sep 10, 2026

A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

A Phase 2 interventional study of zovaglutide Arm 1 and zovaglutide Arm 2 in Obesity, sponsored by Beijing QL Biopharmaceutical Co.,Ltd. Not yet recruiting at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Beijing QL Biopharmaceutical Co.,Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd — 2 open to participants now, 7 under way, 1 of them phase 3. Obesity · Beijing QL Biopharmaceutical Co.,Ltd.

Planned enrollment
3rd of 10
210 · median 77
Started
2026
with 5 others
Phase 2
3 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, this one is the 3rd largest by planned enrollment, is one of 6 that started in 2026, is one of 3 in phase 2, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged≥18years and≤75 years at the time of signing the Form (ICF).
  • At screening, (BMI)≥28kg/m²
  • Weight change due to diet and exercise alone within 3 months prior to screening did not exceed 5%.

Exclusion criteria

Exclusion Criteria:

  • Previously diagnosed obesity caused by monogenic mutations, other diseases, or medications.
  • Previous diagnosis of diabetes; or ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/L at screening.
  • Used of medicines or treatments that affect weight within 3 months prior to screening.
  • History of acute or chronic pancreatitis, or pancreatic injury.
  • History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.
  • History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.
  • Patient Health Questionnaire-9 (PHQ-9) scale score is ≥ 15 at screening
  • Screening Columbia-Suicide Severity Rating Scale(C-SSRS) questionnaire suicide ideation response of "Category 4 or 5," or any "yes" response to suicidal behavior questions
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    zovaglutide Arm1

    Participants will receive zovaglutide dosing schedule 1 after randomization.

    Drug: zovaglutide Arm 1

  • Experimental
    zovaglutide Arm2

    Participants will receive zovaglutide dosing schedule 2 after randomization.

    Drug: zovaglutide Arm 2

  • Active comparator
    semaglutide Arm

    Participants will receive semaglutide once weekly after randomization

    Drug: semaglutide

Interventions

  • Zovaglutide will be administered via subcutaneous (SC) injection.

    Also known as: ZT002 Injection

  • Zovaglutide will be administered via subcutaneous (SC) injection.

    Also known as: ZT002 Injection

  • Semaglutide will be administered via subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization

    Measure description:Definition of successful switch: Participants administered the target dose of assigned zovaglutide at both week28 and week32.

    Time frame: from week 20 (randomization) to week 36

Secondary outcomes

  1. Proportion of participants achieving successful switch without severe gastrointestinal adverse event (GIAE)

    Time frame: from week 20 (randomization) to week 36

  2. Proportion of participants achieving successful switch without dose modification

    Time frame: from week 20 (randomization) to week 36

  3. Incidence of GIAE

    Time frame: from week 20 (randomization) to week 40

  4. Percentage of GIAE-free duration relative to total period after randomization

    Time frame: from week 20 (randomization) to week 40

  5. Changes in body weight from randomization

    Time frame: from week 20 ( randomization) to week 36

07

Study locations

16 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2028, 15 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 15 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 10, 2026
StartEst.
Oct 12, 2026
Primary completionEst.
Jan 13, 2028
CompletionEst.
Mar 24, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07812597
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Oct 12, 2026 (estimated)
Primary completion
Jan 13, 2028 (estimated)
Completion
Mar 24, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Xiaoming Feng
Contact
feng.xiaoming@qlbiopharm.com
+8613932155055
Fengtai Xue
Contact
fengtai@qlbiopharm.com
+8618801907066
Linong Ji, Doctor
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZT002

Start the discussion